Canthin-6-Ones: Potential Drugs for Chronic Inflammatory Diseases by Targeting Multiple Inflammatory Mediators

Zongying Zhang1, Anqi Wang1, Yunhan Wang1

  • 1Department of Immunology, School of Medicine, Nantong University, 19 Qixiu Road, Nantong 226001, China.

Insights

Canthin-6-ones, a class of β-carboline alkaloids, show potential in treating chronic inflammatory diseases (CID). This review summarizes their anti-inflammatory effects and mechanisms, including NLRP3 inflammasome and NF-κB pathways.

Area of Science:

  • Pharmacology
  • Immunology
  • Natural Products Chemistry

Background:

  • Chronic inflammatory diseases (CID) involve recurrent inflammation due to immune system dysregulation.
  • Effective CID management requires controlling immune cell activation and inflammatory responses.
  • Canthin-6-ones are β-carboline alkaloids with emerging evidence of anti-inflammatory properties.

Purpose of the Study:

  • To review and summarize the anti-inflammatory functions of canthin-6-ones.
  • To elucidate the underlying molecular mechanisms of their therapeutic effects.
  • To discuss limitations and future research directions for canthin-6-one applications in CID.

Main Methods:

  • Literature review of in vitro and in vivo studies on canthin-6-ones and inflammation.
  • Analysis of affected disease entities and inflammatory mediators.
  • Focus on key signaling pathways, including NLRP3 inflammasome and NF-κB.

Main Results:

  • Canthin-6-ones demonstrate therapeutic potential across various inflammatory conditions.
  • Key mechanisms involve modulation of the NLRP3 inflammasome and NF-κB signaling pathways.
  • Evidence suggests canthin-6-ones can inhibit aberrant immune system activation.

Conclusions:

  • Canthin-6-ones represent a promising class of compounds for CID treatment.
  • Further research is needed to overcome study limitations and explore therapeutic applications.
  • Understanding mechanisms can guide future drug development for inflammatory diseases.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
185
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
210
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
164
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
161
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
186
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
514